DeepMed Research

Pazopanib

Generic Name: Pazopanib

Brand Names: Votrient

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₃N_₇O_₂S

CAS Number: 444731-52-6

Unique Ingredient Identifier: 7RN5DR86CK

Background: Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication: Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions: Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer

Clinical Trials

A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.

Phase 1

Completed

Conditions: Macular Degeneration
Age-related Macular Degeneration

First Posted Date: 2007-04-20

Last Posted Date: 2012-03-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 29

Registration Number: NCT00463320

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Phase 2

Completed

Conditions: Advanced Malignant Mesothelioma
Recurrent Malignant Mesothelioma
Localized Malignant Mesothelioma

Interventions: Other: laboratory biomarker analysis
Drug: pazopanib hydrochloride

First Posted Date: 2007-04-13

Last Posted Date: 2015-02-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT00459862

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Pazopanib in Treating Patients With Recurrent Glioblastoma

Phase 2

Completed

Conditions: Recurrent Adult Brain Tumor
Adult Gliosarcoma
Adult Glioblastoma
Adult Giant Cell Glioblastoma

Interventions: Drug: pazopanib hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2007-04-11

Last Posted Date: 2017-03-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00459381

Locations: 🇺🇸
National Cancer Institute Neuro-Oncology Branch, Bethesda, Maryland, United States
🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States

and more 6 locations

Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

Phase 2

Completed

Conditions: Recurrent Prostate Cancer

Interventions: Drug: leuprolide acetate
Drug: pazopanib hydrochloride
Drug: goserelin acetate

First Posted Date: 2007-03-30

Last Posted Date: 2016-02-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00454571

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

Phase 2

Completed

Conditions: Gastrin-Producing Neuroendocrine Tumor
Lung Carcinoid Tumor
Metastatic Digestive System Neuroendocrine Tumor G1
Multiple Endocrine Neoplasia Type 1
Pancreatic Glucagonoma
Pancreatic Insulinoma
Pancreatic Polypeptide Tumor
Recurrent Digestive System Neuroendocrine Tumor G1
Recurrent Pancreatic Neuroendocrine Carcinoma
Regional Digestive System Neuroendocrine Tumor G1

Interventions: Other: Laboratory Biomarker Analysis
Drug: Pazopanib Hydrochloride
Other: Pharmacological Study

First Posted Date: 2007-03-30

Last Posted Date: 2020-04-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT00454363

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer

Phase 2

Completed

Conditions: Stage IV Lymphoepithelioma of the Nasopharynx
Stage IV Squamous Cell Carcinoma of the Nasopharynx
Recurrent Lymphoepithelioma of the Nasopharynx
Recurrent Squamous Cell Carcinoma of the Nasopharynx

Interventions: Drug: pazopanib hydrochloride
Other: pharmacological study
Procedure: computed tomography

First Posted Date: 2007-03-30

Last Posted Date: 2015-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT00454142

Locations: 🇸🇬
Cancer Therapeutics Research Group, Singapore, Singapore
🇸🇬
National University Hospital, Singapore, Singapore
🇸🇬
National Cancer Centre, Singapore, Singapore

Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery

Phase 1

Terminated

Conditions: Stage IIA Breast Cancer
Male Breast Carcinoma
Recurrent Breast Carcinoma
Stage IIB Breast Cancer
Stage IA Breast Cancer
Stage IB Breast Cancer
Stage IIIA Breast Cancer

Interventions: Drug: Pazopanib Hydrochloride
Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis

First Posted Date: 2007-03-22

Last Posted Date: 2015-03-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00450879

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

Phase 2

Completed

Conditions: Neoplasms, Uterine Cervix
Metastatic Cervical Cancer

Interventions: Drug: pazopanib (GW786034)
Drug: lapatinib (GW572016)

First Posted Date: 2007-02-02

Last Posted Date: 2015-05-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 228

Registration Number: NCT00430781

Locations: 🇹🇭
GSK Investigational Site, Khon Kaen, Thailand

Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer

Phase 3

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: pazopanib

First Posted Date: 2006-10-13

Last Posted Date: 2014-01-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 80

Registration Number: NCT00387764

Locations: 🇬🇧
GSK Investigational Site, Manchester, United Kingdom

Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)

Phase 1

Completed

Conditions: Neoplasms, Colorectal

Interventions: Drug: Pazopanib
Drug: FOLFOX 6
Drug: CapeOx

First Posted Date: 2006-10-13

Last Posted Date: 2017-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 50

Registration Number: NCT00387387

Locations: 🇬🇧
GSK Investigational Site, Sutton, Surrey, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy